TrichoFoam™ is a stable option for personalized hair loss treatment with most ingredients remaining effective for 90-180 days.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
25 citations
,
September 2014 in “Pharmacotherapy” Hormone therapy can improve mental health and quality of life for people with gender dysphoria, but long-term effects need more research.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
September 2018 in “The Journal of Urology” Clomiphene citrate is a cheap and simple treatment for low testosterone that works as well as human chorionic gonadotropin, alone or combined, especially for men who want to keep their fertility.
18 citations
,
January 2002 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
125 citations
,
May 2019 in “Phytomedicine” Cepharanthine is a well-tolerated drug with multiple medical uses, including anti-inflammatory and anti-cancer properties.
127 citations
,
May 2004 in “PubMed” Finasteride may help some male chronic pelvic pain patients, but more research needed.
January 2018 in “Urologe A” Botulinum neurotoxin injections into the pelvic muscles successfully prevented priapism relapse for over six months.
16 citations
,
January 2019 in “Pharmaceutical biology” Lespedeza cuneata extract may help treat enlarged prostate.
1 citations
,
November 1987 in “Journal of The American Academy of Dermatology” Isotretinoin can raise CPK levels, so patients need monitoring, especially before surgery.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
22 citations
,
October 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Combining isotretinoin and dapsone effectively treated a challenging scalp condition.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
30 citations
,
February 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Some medications can reduce excessive hair growth in women, but more research is needed to find the best treatment combinations.
3 citations
,
July 2023 in “International Journal of Trichology” DPCP can help regrow hair in some people with severe alopecia.
4 citations
,
September 2011 in “American Journal of Clinical Dermatology” Ethinylestradiol/chlormadinone acetate may be an effective and well-tolerated treatment for skin conditions caused by excess androgens.
November 2023 in “PubMed” Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.
November 2017 in “Reactions Weekly” Testosterone undecanoate caused hair loss; finasteride improved it but caused stomach issues for one patient.
2 citations
,
October 2021 in “Clinical and experimental dermatology” Cyperus rotundus essential oil effectively treats underarm darkening, reduces inflammation, and slows hair growth.
117 citations
,
May 2017 in “Human Reproduction Update” The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.
June 2014 in “Reactions Weekly”
August 2024 in “Medicine” Most patients with PCOS were prescribed medroxyprogesterone acetate or oral contraceptives, with some experiencing side effects or needing prescription changes.
April 2026 in “Reactions Weekly” December 2024 in “Reactions Weekly” November 2014 in “Reactions Weekly” July 2014 in “Reactions Weekly” August 2013 in “Reactions Weekly” January 2013 in “Reactions Weekly”